Celltrion, which sells a cheap version of a top-selling rheumatoid arthritis drug in Europe, is now setting its sights on the U.S.
Similar Stories to Celltrion Seeks Fda Approval For Biosimilar Remsima on Bing News
WSJ.com: Asia Home, Wall Street Journal: Home Asia
Tue, 03/31/2015 - 11:40pm
RELATED ARTICLES
- Stocks Fall as Investors Pause on Trade
Stocks fell, erasing early gains as investors continued to track trade negotiations between the U.S. and China as the two nations appear to inch closer to a pact. More - House Panel Requests Documents From Associates of Trump
Democrats intensified their investigations into President Trump and his associates, with House committees demanding records related to his business dealings, interactions with the Justice Department and communications with Russian President Vladimir Putin. More - U.S. Probes Titanium Imports in Possible Tariff Case
The Commerce Department will look into potential national-security risks in imports of the metal at the request of domestic producer Timet. More - China Accuses Detained Canadians of Espionage
China accused two detained Canadians of working together to steal Chinese state secrets, moving ahead with a politically charged investigation seen as retribution for Canada’s arrest of a senior Huawei executive. More - North Korea Still Using Uranium-Enrichment Facility, U.N. Agency Says
North Korea is still using a uranium-enrichment facility at the heart of last week’s summit between President Trump and North Korean leader Kim Jong Un, the United Nations atomic agency said. More - Purdue Pharma Preparing Possible Bankruptcy Filing
Purdue Pharma is working with advisers on a possible bankruptcy filing as it seeks to contain liability from suits alleging it fueled the U.S. opioid epidemic. More
BING NEWS:
- FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
05/2/2024 - 5:38 am | View Link - FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira
Boehringer Ingelheim on Wednesday won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.
05/2/2024 - 12:37 am | View Link - Accord BioPharma get FDA OK for Herceptin biosimilar
Shanghai Henlius Biotech’s partner, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has received permission from the Food and Drug Administration for Hercessi (HLX02, ...
04/30/2024 - 2:06 am | View Link - FDA Approves Hercessi, the Sixth Trastuzumab Biosimilar
The recent FDA approval of Hercessi expands access to a treatment previously burdened by high costs. Hercessi joins the 5 other biosimilars already on the market.
04/29/2024 - 5:02 am | View Link - FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast and gastric cancers.
04/29/2024 - 2:59 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more